Amino acids are the basic structural units of proteins, which are critical macromolecules of all living organisms. Proteins play a role in almost every aspect of biological function, and structure and function are conferred by the sequence and nature of amino acids. Read the detailed description of amino acids. Structure […]
AstraZeneca’s Calquence-based fixed-duration regimens gain EU approval for treating first-line CLL, offering patients a powerful, time-limited alternative to traditional continuous therapy.
Sanofi unveiled promising new data at ISTH 2025, spotlighting rilzabrutinib’s potential in immune thrombocytopenia and reinforcing its leadership in hemophilia care through advancements with ALTUVIIIO and QDENGA.
Researchers at UPMC and Penn State have developed a new mRNA vaccine platform that is more scalable and adaptable, offering rapid protection against viruses like COVID-19 and H5N1.
Roche’s Evrysdi® 5mg tablet for spinal muscular atrophy receives European Commission approval, offering a convenient, room-temperature stable treatment option for patients aged 2 and above.
Johnson & Johnson reports a 95% four-year progression-free survival rate using the DARZALEX FASPRO®-based regimen in transplant-eligible, newly diagnosed multiple myeloma patients who achieved sustained MRD negativity.
Amgen has revealed ground-breaking findings from its Phase 3 DeLLphi-304 clinical trial, showing that Imdelltra® (tarlatamab-dlle) dramatically decreased the risk of death in patients with extensive-stage small cell lung cancer (ES-SCLC) by 40% when compared to standard chemotherapy. Patients whose illness had worsened after receiving platinum-based chemotherapy were included in […]
The first stage of mitosis and meiosis, two crucial cellular division processes that support an organism’s growth, repair, and reproduction, is known as prophase.The specifics of what transpires and why differ depending on the cell’s activity in either mitosis or meiosis, even though chromosomal condensation and spindle construction are shared […]
Roche’s Itovebi™ (inavolisib) significantly improved overall survival in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer patients, according to final Phase III INAVO120 trial results.
Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.
